viewAllergy Therapeutics PLC

Allergy Therapeutics sees sales grow in all countries

Revenues rose by 9% in the six months to December to £50.5mln

Allergy Therapeutics PLC -
Phase III trial will cover two pollen seasons

Allergy Therapeutics PLC (LON: AGY) has continued to notch up good growth while it prepares for the phase III trial of its hay fever vaccine later this year.

Revenues in the six months to December 31 2019 rose by 9% to £50.5mln with growth across all major countries, though Germany, Spain, Netherlands and Switzerland did the best.

The group's Pollinex Quattro and sting treatment Venomil were the best performers.

Cash at the end of December was £39.7mln which will suffice to fund the Grass MATA MPL Phase III trial, the company said.

Allergy recently took the decision to split this trial over two years to assess its efficacy during two pollen seasons.

The split option also gives it an opportunity to assess progress at the trial’s halfway point. 

Allergy said it has also now received regulatory support for a phase I trial of a new peanut allergy vaccine. 

Manuel Llobet, the firm's chief executive, said: "This represents another six months of consistent growth reflecting the quality of our platform and our team.

“Despite an evolving regulatory environment, we continue to perform well and we have great confidence in our commercial abilities and clinical pipeline."

Quick facts: Allergy Therapeutics PLC

Price: 11.15 GBX

Market: AIM
Market Cap: £70.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Allergy Therapeutics confident on the coming year as it reports 8% boost to...

Allergy Therapeutics PLC's (LON:AGY) Manuel Llobet and Nick Wykeman talk Proactive London's through the firm's preliminary results to June 2019. The vaccines specialist posted an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of...

on 25/9/19

2 min read